Page 4 - Nyse Ebs News Today

If approved by the FDA, NARCAN Nasal Spray will be the first 4 mg naloxone nasal spray switched from prescription status to over-the-counter use ...

GAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery,...

GAITHERSBURG, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in...

GAITHERSBURG, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive...

GAITHERSBURG, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company’s executive...

Shares of Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) have earned a consensus recommendation of “Hold” from the nine research firms that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month […]

Emergent BioSolutions (NYSE:EBS – Get Rating) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Saturday. A number of other research analysts also recently commented on the company. Wells Fargo & Company lowered their price objective on Emergent BioSolutions from $46.00 to $38.00 in a research […]

Emergent BioSolutions Inc. (NYSE:EBS – Get Rating) – Investment analysts at Cantor Fitzgerald lowered their FY2022 earnings per share (EPS) estimates for Emergent BioSolutions in a note issued to investors on Monday, May 2nd. Cantor Fitzgerald analyst B. Folkes now expects that the biopharmaceutical company will post earnings per share of $1.31 for the year, […]

Cantor Fitzgerald lowered shares of Emergent BioSolutions (NYSE:EBS – Get Rating) from an overweight rating to a neutral rating in a research note issued to investors on Friday, MarketBeat reports. A number of other brokerages have also issued reports on EBS. Cowen cut their price target on Emergent BioSolutions from $40.00 to $30.00 in a […]

Emergent BioSolutions (NYSE:EBS – Get Rating) is set to post its quarterly earnings results after the market closes on Thursday, April 28th. Analysts expect Emergent BioSolutions to post earnings of $0.23 per share for the quarter. Emergent BioSolutions has set its Q1 2022 guidance at EPS and its FY 2022 guidance at EPS.Persons interested in […]